Alzheimer’s disease has proved to be a tricky target, and researchers and drug developers have been pursuing effective treatments for decades. The brains of people who die with Alzheimer’s show a ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...